Show summary Hide summary
- Why the change is arriving now: audits, targets and the 2026 budget
- Which everyday medicines will be affected by the cut
- Thermal cures under review: a costly change for patients
- Who is most exposed: chronic patients and household budgets
- How health authorities decide what to delist
- Concrete effects for patients and tips to limit extra costs
- The bigger picture: shifting priorities in health financing
From February 1, 2026, many familiar over-the-counter and prescribed products will cost patients more. A government plan to trim health spending will change how common remedies and even some chronic-care supports are covered by French health insurance.
Why the change is arriving now: audits, targets and the 2026 budget
Two state audit teams reviewed public health spending and flagged items seen as low priority.
Eggs every day for months: simple check reveals shocking blood test result
Popular childhood food ingredient may raise adult anxiety: study
The move forms part of a broader plan to save €5.5 billion in 2026. Authorities say targeting low-value reimbursements is a fast way to reduce outlays.
Inspectors estimate that trimming reimbursements for certain medicines could save almost €90 million a year. The aim is to refocus funds on drugs with proven benefit.
Which everyday medicines will be affected by the cut
Several products commonly kept in home medicine cabinets are on the list. Examples include:
- Gaviscon, for heartburn and reflux
- Spasfon, for digestive spasms and menstrual pain
- Dexeryl, an emollient cream for dry skin
- Bétadine, a routine antiseptic for minor wounds
Until now, patients with a long-term condition benefited from 100% coverage for many of these items. From 1 February 2026, coverage for the listed products will drop to 15% for everyone.
Example: a medicine costing €10 that was effectively free could rise to about €8.50 out of pocket for the patient.
Thermal cures under review: a costly change for patients
Thermal spa treatments are also targeted for reduced support. These cures often require travel and lodging.
Patients with long-term conditions who once received full coverage will now see their reimbursement fall to 65%.
Because a cure can cost several hundred euros, a remaining 35% share will be significant for low-income households. The government projects around €25 million in annual savings from this adjustment.
Who is most exposed: chronic patients and household budgets
About 14 million French citizens live with an affection of long duration (ALD). Many will lose a symbolic financial protection.
For people with chronic disease, repeated purchases add up. Complementary health plans do not always cover these items unless a special option is selected.
Pharmacies warn that small, recurring costs can become a heavy burden over time.
How health authorities decide what to delist
The Haute Autorité de Santé assesses a medicine’s clinical benefit, known as the service médical rendu (SMR).
A low SMR means a product offers limited symptom relief, has restricted therapeutic effect, or is superseded by better alternatives.
Medications labelled as low SMR are not considered useless. They are judged less essential compared with higher-value treatments.
Concrete effects for patients and tips to limit extra costs
Coverage rules will shift as follows:
- ALD patients: items no longer fully reimbursed; out-of-pocket depends on your mutuelle.
- Other insured: standard rate set at 15% with prescription; possibly 0% without one.
Practical tips to reduce the bill:
- Review your complementary insurance for a pharmacy or self-care allowance.
- Ask your doctor about therapeutic alternatives or generic options.
- Compare prices across pharmacies and online platforms where allowed.
- Keep prescriptions and receipts to challenge billing errors.
What insurers and pharmacies may offer
Some private plans now include a “self-medication” package. Pharmacies may propose generics or cheaper formats.
But these options often require active subscription or specific contractual clauses.
The bigger picture: shifting priorities in health financing
The official logic is to concentrate public money on treatments with clear, documented benefit. New medicines and innovations are the main beneficiaries.
At the same time, the national health model moves toward more patient cost-sharing. The rollout of the digital Vitale card aims to streamline claims and limit fraud.
For many citizens, reduced coverage feels like a subtle erosion of social solidarity — fewer services covered, higher personal expense.
